Skip to content
Peptigraph home

Orforglipron vs Semaglutide: What the Research Shows

Orforglipron and Semaglutide side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Oral small-molecule GLP-1 agonistFDA approved (Foundayo, Apr 2026)OrforglipronOral small-molecule GLP-1 receptor agonist FDA-approved as Foundayo; in a large trial mean weight change at week 72 was -7.5% on 6 mg and -8.4% on 12 mg.[16]GLP-1 & metabolic+30% searchesGLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[17]GLP-1 & metabolic−38% searches
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Orforglipron if…

  • you want an FDA-approved oral option: Foundayo (orforglipron) is labelled, with diet and activity, to reduce excess body weight in adults with obesity or with overweight plus a weight-related condition[6]
  • you want an oral option with randomized weight-loss data: Body weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72.[16]

Consider Semaglutide if…

  • you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[15]
  • you want cardiovascular-outcomes data in obesity without diabetes: The primary cardiovascular composite occurred in 6.5% on semaglutide vs 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90).[18]

What they have in common

  • In the ACHIEVE-3 head-to-head trial, HbA1c changed by -1·91% with orforglipron 36 mg vs -1·47% with semaglutide 14 mg at week 52[8]
Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

FieldOrforglipronSemaglutide
ClassOral small-molecule GLP-1 agonistGLP-1 agonist
Also calledFoundayo, orfosema, Ozempic, Wegovy, Rybelsus, Wegovy pill
FDA statusFDA approved (Foundayo, Apr 2026)FDA approved (Ozempic, Wegovy, Rybelsus)
Half-lifeapproximately 29 to 49 hoursoral · FDA label (Foundayo)approximately 1 weeksubcutaneous · FDA label (Ozempic)
Human studies we summarised14 human (13 randomized or controlled) of 15 summarised23 human (19 randomized or controlled) of 27 summarised
Typical study doses
US searches per month27,100 · +30% searches368,000 · −38% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
  4. 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  5. 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  6. 6These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  7. 7Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  8. 8Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
  9. 9Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
  10. 10These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  11. 11Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  12. 12Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  13. 13Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  14. 14PubMed search: (orforglipron[tiab] OR LY3502970[tiab] OR Foundayo[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  16. 16Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
  17. 17Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  18. 18Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026

Found an error? Report a correction.